EP
PACB icon

Essential Partners’s Pacific Biosciences PACB Stock Holding History

Essential Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$958 Sell
570
-18,045
-97% -$26.2K ﹤0.01% 2263
2026
Q1 		$24.6K Buy
+18,615
New +$33.3K 0.01% 850

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Essential Partners's PACB Position: Q2 2026 in Review

Essential Partners reduced its Pacific Biosciences (PACB) stake by 97% in Q2 2026, selling an estimated $26.2K and leaving 570 shares worth $958. The position accounts for ﹤0.01% of the portfolio, ranked #2263.

Essential Partners first reported a position in PACB in Q1 2026 and has held it in 2 quarters since. The position peaked at $24.6K in Q1 2026. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Essential Partners held 570 shares of Pacific Biosciences worth $958 as of Q2 2026.
  • Essential Partners sold 18,045 Pacific Biosciences shares in Q2 2026, an estimated $26.2K.
  • Pacific Biosciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2263 holding.
  • Essential Partners first reported a position in Pacific Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Essential Partners's Pacific Biosciences position peaked at $24.6K in Q1 2026.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.